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Objective: To report a case of isolated omental peritoneal carcinoma without peritoneal carcinomatosis.
Case report: A 60-year-old female with abdominal distention was found to have a pelvic mass. Under the
impression of ovarian cancer, laparotomy was performed only to show one isolated mass over omentum.
Serial examination and pathology study including immunochemical staining indicated primary perito-
neal serous carcinoma.
Conclusion: Isolated omental peritoneal carcinoma without peritoneal carcinomatosis and ascites is rare,
and whether this represented a unique entity with different chemotherapy response and treatment
outcome from the disseminated form of primary peritoneal carcinoma needs to be reviewed in the
future.
Copyright © 2014, Taiwan Association of Obstetrics & Gynecology. Published by Elsevier Taiwan LLC. All
rights reserved.Introduction
Primary serous peritoneal carcinoma (PSPC) is a malignancy
that originates from the peritoneumwith typical features of diffuse
peritoneal involvement and ascites. Despite the common clinical
features shared by PSPC and epithelial ovarian carcinoma, the
incidence of PSPC is considerably lower than that of epithelial
ovarian carcinoma (6.78 cases per million vs. 120.5 cases per
million, respectively) [1]. However, the true incidence of PSPC is
unknown owing to inconsistent deﬁnitions and diagnostic criteria
from retrospective data. The most common presenting symptoms
of PSPC are abdominal distension (59.1%) and abdominal pain
(19.0%), and ascites are present in 63.6% of cases [2]. Almost all
cases of PSPC involve disseminated disease at diagnosis [3]; only a
few cases of solitary PSPC have been reported.
We report a case of PSPC mimicking a solitary pelvic tumor with
an unusual pattern of spread. To the best of our knowledge, primary
peritoneal carcinoma developing on the omentum as a single tu-
mor without peritoneal carcinomatosis has not previously been
reported. At present, limited data are available with regard to the
optimal treatment strategy and prognosis of localized primarys and Gynecology, National
, Zhongzheng District, Taipei
Cheng).
bstetrics & Gynecology. Publishedperitoneal carcinoma. Despite its rarity, isolated omental peritoneal
carcinoma should be included in the differential diagnosis of pelvic
tumors. This case could provide a new paradigm for isolated peri-
toneal carcinomas.Case presentation
A 60-year-old woman, gravida 5 parity 2, came to our hospital
because of a recent diagnosis of a pelvic tumor. She had been well
until 6 months earlier when low abdominal discomfort developed,
followed by abdominal distention. One week prior to this consul-
tation, she noted a mass over her right lower abdomen. An evalu-
ation at a local clinic led to the diagnosis of a pelvic tumor, and she
was referred to our hospital.
Menopause had occurred at the age of 51 years without hor-
mone replacement therapy. There was no abnormal bleeding or
change in bowel or bladder habits, and results of general exami-
nations were normal. On gynecologic examination, her uterus was
found to be of normal size, although a ﬁrm and movable adnexal
mass about fetal head in size was noted without motion tender-
ness. Transvaginal and transabdominal ultrasonography showed a
9.1 cm  8.9 cm right adnexal solid tumor with an irregular border
and heterogeneous content. Data taken from her chest X-ray,
electrocardiogram, complete blood count, serum electrolyte mea-
surements, and liver and renal-function tests were within normal
limits. Tumormarkers were checkedwith amild elevation of serumby Elsevier Taiwan LLC. All rights reserved.
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level of carcinoembryonic antigen (1.54 ng/mL; normal range
<2.5 ng/mL). Computed tomography (CT; Fig. 1) of the abdomen
and pelvis showed a large pelvic mass of about 12 cm, extending to
the right lower abdomen with a cystic component and heteroge-
nous enhancement. Diffuse peritoneal thickening and omental
inﬁltration suggested right ovarian cancer with cancerous perito-
nitis. There were no ascites or deﬁnite lymphadenopathy.
On laparotomy, a solitary solid mass arising from the omentum
was identiﬁed (Fig. 2A and B). The tumor was whitish in color with
some central yellow necrosis. The uterus and bilateral adnexa were
intact without tumor involvement. A thorough inspection of the
abdomen and pelvic cavity revealed no gross tumor seeding or
metastases. Intraoperatively, a frozen section of the tumor showed
high-grade carcinoma. Omentectomy, total abdominal hysterec-
tomy, bilateral salpingo-oophorectomy, and pelvic and para-aortic
lymph-node dissection were then performed, with optimal
debulking surgery without gross residual tumor. A pathological
examination revealed extensive necrosis (Fig. 3A) of the tumor that
was composed of pleomorphic and hyperchromatic cells with brisk
mitosis (Fig. 3B). The frequent sarcomatoid features of tumor spin-
dling and bizarre giant cells were also noted. Immunohistochemi-
cally, these neoplastic cells showed diffusely and strongly positive
for p53 (Fig. 4A), p16 (Fig. 4B), and PAX-8. However, peritoneal
malignant mesothelioma markers including cytokeratin 5/6
(Fig. 4C) or calretinin (Fig. 4D) were negatively stained. No
neoplastic cells were seen in bilateral ovaries, and no in situ
adenocarcinomawas identiﬁed at bilateral fallopian tubes or uterus.
Both cytological and histopathological examinations of peritoneal
washings and regional lymph nodes yielded negative results for
malignant cells or metastatic cancer cells. A high-grade primary
peritoneal serous carcinoma, FIGO (International Federation of
Gynocology and Obstetrics) stage IIIC (pT3N0M0), was thus diag-
nosed. Chemotherapy with paclitaxel (175 mg/m2) and carboplatin
(area under the curve¼ 6) every 3weekswas arranged for six cycles.Fig. 1. Computed tomographic scan showed one 10-cm hypervascular, heterogeneous
mass (arrow) in the right lower pelvic cavity.The serum CA-125 level normalized after the surgery, and therewas
no evidence of recurrence after 6 months of follow-up.
Discussion
PSPC, ﬁrst described in 1959 [4], is a malignancy arising from
extraovarian mesothelial cells with müllerian potential, and
different nomenclatures have been used including serous surface
papillary carcinoma, primary peritoneal carcinoma, extraovarian
pelvis serous carcinoma, and psammomacarcinoma [5]. A diagnosis
of primary peritoneal carcinoma is based on the Gynecologic
Oncology Group criteria: (1) both ovaries are normal in size or
enlarged by a benign process; (2) extraovarian involvement is
greater than ovarian involvement; (3) absence of deep-seated
invasive ovarian carcinoma or cortical invasion with tumors that
measure less than 5  5 mm2; and (4) the tumor is of a serous cell
type [6]. Our case ﬁt these criteria as the omental mass showed
serous carcinoma without other organ involvement.
The most common presenting symptoms of PSPC are abdominal
distension, abdominal pain, and poor appetite. The differential
diagnosis of a solitary pelvic mass includes pedunculated uterine
ﬁbroid and ovarian tumors. Typical ﬁbroid tumors are well-deﬁned
masses of low-signal intensity compared to the myometrium on
magnetic resonance imaging T2-weighted images. Pelvic exami-
nations may give a clue to the diagnosis; however, occasionally the
correct diagnosis is not made until the surgery. The typical CT
features of PSPC are a large volume of ascites, mesenteric or
omental mass, peritoneal thickening, and lack of an obvious ovarian
tumor. However, the CT ﬁndings were misleading in our case
because there were no ascites or classic “omental cake” appearance
except for one pelvic mass.
PSPC is clinically and histologically difﬁcult to differentiate from
stage III or IV ovarian serous papillary carcinoma (OSPC). A pre-
operative diagnosis is unlikely to be based solely on image ﬁndings;
nonetheless, exploratory laparotomy can offer a diagnosis and
staging evaluation. However, PSPCwith distant metastasis at pleura
and supraclavicular lymph node but without peritoneal carcino-
matosis had been reported in two cases [7,8]. Kim et al [9] reported
the ﬁrst case of the localized form of PSPC, which was a single
primary tumor originating from the peritoneal lining of the sigmoid
colon. Our case is unique in its presentation of an isolated omental
mass without peritoneal spread. To the best of our knowledge,
there have not been any reported cases of solitary primary peri-
toneal carcinoma arising from the omentum.
Pretreatment CA-125 level is an effective tumor marker for
diagnosing, correlating with clinical status, and reﬂecting disease
dissemination. Preoperative CA-125 values have been reported to
be signiﬁcantly elevated in 90.5% of PSPC patients with all stages,
and in 95% of patients with stages IIeIV [2]. Roh et al [10] reported
that 21 out of 22 PSPC patients had elevated preoperative CA-125
values with a median value of 706 U/mL (range, 35e7647 U/mL).
CA-125 level can also be used for the evaluation of treatment
response and disease recurrence [11]. The solitary PSPC patient
reported by Kim et al [9] also showed a slightly elevated serum CA-
125 level of 44.6 U/mL. In our case, the preoperative serum CA-125
level was also slightly elevated at 56.9 U/mL, which dropped to
13.4 U/mL after six cycles of adjuvant chemotherapy. CA-125 could
therefore have been used as a surrogate marker for this patient.
The treatment and prognosis of PSPC are similar to OSPC with
platinum-based chemotherapy as prescribed in our patient. Ayhan
et al [12] reported 32 PSPC and 43 OSPC patients who received
adjuvant cisplatin (carboplatin) and paclitaxel after cytoreductive
surgery. No signiﬁcant differences were noted with respect to
clinical or surgical response, progression-free survival (14 months
for both groups), or overall survival (30 months for PSPC and 28
Fig. 2. (A) A solitary mass was noted arising from the omentum. There was no omental caking or inﬁltration. (B) Cut surface of the resected tumor showed a whitish solid with
extensive necrosis with foci of calciﬁcation.
Fig. 3. (A) A well-demarcated tumor (arrow) with prominent necrosis arising from the omentum [hematoxylin and eosin (H&E) stain,  40]. (B) The tumor was composed of high
grade nuclei, and giant cells with multipolar mitosis (H&E stain,  200).
Fig. 4. The tumor cells were diffusely positively immunostained for (A) p53 (100) and (B) p16 (100), and negative for (C) cytokeratin 5/6 (100) and (D) calretinin (100).
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indicated similar progression-free survival for advanced PSPC and
OSPC patients but a shorter overall survival in the PSPC group
possibly because of the older mean age and higher tumor grade in
this study [13]. The case reported by Kim et al [9] received no
adjuvant therapy except for surgical staging with a 5-year remis-
sion period. Although no grossly residual tumor with negative
peritoneal washing cytology was observed in our patient, owing to
its rarity, we still gave her adjuvant chemotherapy. Whether
localized PSPC can be regarded as a unique clinical entity without
adjuvant chemotherapy requires further investigations.Conﬂicts of interest
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